-Reuters
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
The FDA has put Foghorn Therapeutics Inc’s (NASDAQ:FHTX) study on partial hold after a patient had a severe heart-related safety event.…